PFE

Pfizer: Obesity Hype And Vaccine Policy Shocks (Archive)

Pfizer’s obesity and vaccine setbacks outweigh cheap valuation, pointing to renewed underperformance risk.

Pfizer: Adjusted EPS Masks How Bad 2026 Really Looks (Archive)

Pfizer’s 2026 earnings reality looks far uglier than headline adjusted EPS suggests.

Did Pfizer Overpay For Yet Another Acquisition? (Archive)

Pfizer’s Metsera obesity deal looks reasonably priced, but fundamentals still justify only a hold.

Pfizer's Q1 Update May Mark A Bottom In The Stock (Archive)

Pfizer’s valuation and cost cuts hint at a forming bottom despite structural headwinds.

Pfizer: 3 Key Risks That Warrant A Sell (Archive)

Patent cliffs, weak margins, and bearish technicals justify maintaining a Sell stance.

Pfizer: Why I'm Staying On The Sidelines (Archive)

Staying on the sidelines despite oncology progress and valuation discount.

Pfizer: Too Early For A Turnaround (Archive)

Pfizer’s oncology pivot and CEO incentives cloud the timing and quality of any turnaround.